KPV

Anti-Inflammatory Tripeptide | Alpha-MSH Fragment

Half-life: 1-2 hours
Chain: 3 amino acids
5 studies
2017 latest
3 recent
Emerging
Dose 200-500 mcg per injection
Frequency 1-2 times daily (once for maintenance, twice for active inflammation)
Cycle 4-8 weeks
Storage Lyophilized: Room temperature. Reconstituted: 2-8°C, refrigerate immediately

Community Research

Join others researching KPV — share findings, ask questions, and learn from real experiences

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.

Mechanism of Action

Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.

01 Systemic anti-inflammatory effects
02 No pigmentation/tanning effects
03 Immune modulation without immunosuppression
04 Potential for autoimmune conditions
05 Gut health support
06 Multiple delivery routes available

Molecular Data

Chain Length
3 amino acids
Type
Tripeptide
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Inflammation
Systemic Inflammation most effective

Reduces TNF-α and IL-6 through NF-κB pathway inhibition.

Autoimmune Modulation effective

May help balance overactive immune responses in autoimmune conditions.

Joint Inflammation effective

Potential benefits for inflammatory arthritis through cytokine reduction.

Gut Health
IBD Support effective

Demonstrated benefit in Crohn's disease and ulcerative colitis models.

Intestinal Barrier Repair effective

Helps restore intestinal barrier function.

Microbiome Balance moderate

Selective antimicrobial activity preserves beneficial gut bacteria.

Skin Health
Psoriasis/Dermatitis effective

Topical KPV reduced psoriatic markers by 60% and improved skin barrier function.

Skin Inflammation effective

Reduces inflammatory skin conditions without systemic effects.

Dosing Protocols

Subcutaneous injection provides systemic anti-inflammatory effects. Abdomen is preferred for gut-related issues.

GoalDoseFrequencyRoute
General anti-inflammatory200-300mcgOnce dailySubQ
Active inflammation250mcgTwice dailySubQ
Autoimmune support500mcgOnce dailySubQ
Acute flare-ups500mcg2x daily for 1 week, then reduceSubQ

Reconstitution Instructions

Materials Needed:
  • KPV lyophilized powder
  • Bacteriostatic water
  • Insulin syringes
  • Alcohol swabs
  1. 1 Clean vial with alcohol pad
  2. 2 Add 1mL bacteriostatic water to 1mg vial (1000mcg/mL)
  3. 3 Or add 2mL for 500mcg/mL concentration
  4. 4 Gently swirl - dissolves easily
  5. 5 Solution should be clear and colorless
  6. 6 Label with concentration and date
  7. 7 Refrigerate immediately

Interactions

++
BPC-157
Enhanced gut healing and anti-inflammatory effects through complementary mechanisms.
synergistic
+
TB-500
Different mechanisms; can be combined safely.
compatible
++
LL-37
Complementary antimicrobial and healing effects.
synergistic
+
Thymosin Alpha-1
Both support immune function through different pathways.
compatible
++
GHK-Cu
Synergistic for skin health and regeneration.
synergistic
~
Melanotan II
Both are α-MSH related; KPV lacks pigmentation effects but monitor for cumulative effects.
monitor

What to Expect

Days 1-3
Subtle reduction in inflammation, improved energy
Week 1
Noticeable decrease in inflammatory symptoms
Week 2-3
Improved gut function (if applicable), reduced pain/swelling
Week 4
Significant improvement in inflammatory markers
Week 6-8
Sustained benefits, improved quality of life

Side Effects & Safety

Common Side Effects

  • Minimal to no side effects reported
  • Does not cause immunosuppression like steroids
  • No melanin production/tanning effects
  • May temporarily reduce inflammation-related symptoms

Stop Signs - Discontinue if:

  • Signs of infection (fever, chills) - very rare
  • Severe injection site reactions
  • Paradoxical inflammation increase
  • Allergic reaction symptoms
  • Unusual fatigue or weakness

Contraindications

  • Known peptide allergies
  • Active severe infections (theoretical)
  • Pregnancy or breastfeeding (limited data)

Quality Checklist

Good Signs

  • High purity >98%
  • Clear, colorless solution after reconstitution
  • Stable small peptide structure
  • Certificate of analysis available

Warning Signs

  • pH should be 5.5-7 for optimal stability

Bad Signs

  • Visible particles indicate contamination/degradation
  • Yellow coloration indicates oxidation/potency loss

References

  • Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) Alpha-Melanocyte-Stimulating Hormone Peptides
    Getting, S.J., Schiöth, H.B., Perretti, M.
    Journal of Pharmacology and Experimental Therapeutics (2003)

    Established that KPV exerts anti-inflammatory effects distinct from core MSH peptides, likely through inhibition of IL-1β functions rather than melanocortin receptor signaling.

  • PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
    Dalmasso, G., et al.
    Gastroenterology (2008)

    KPV is transported into cells via PepT1, where nanomolar concentrations inhibit NF-κB and MAP kinase signaling pathways. Oral KPV reduced DSS- and TNBS-induced colitis in mice.

  • Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease
    Kannengiesser, K., et al.
    Inflammatory Bowel Diseases (2008)

    KPV showed significant anti-inflammatory effects in DSS colitis and CD45RBhi transfer colitis models, reducing weight loss, histological damage, and MPO activity. Effects partially independent of MC1R signaling.

  • Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of KPV
    Viennois, E., et al.
    Cellular and Molecular Gastroenterology and Hepatology (2016)

    PepT1 is highly expressed in human colorectal tumors. PepT1-transported KPV prevented colitis-associated carcinogenesis in wild-type mice, with no effect in PepT1-knockout mice, confirming PepT1-dependent therapeutic mechanism.

  • Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
    Xiao, B., et al.
    Molecular Therapy (2017)

    HA-functionalized KPV nanoparticles (~272.3 nm) successfully targeted colonic epithelial cells and macrophages, exerting combined mucosal healing and anti-inflammatory effects superior to free KPV in a UC mouse model.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.